Applied Therapeutics to Ring Nasdaq Closing Bell on December 17th

December 16, 2019 at 7:00 AM EST

NEW YORK, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Applied Therapeutics Inc. (Nasdaq:APLT), announced today that Shoshana Shendelman, Ph.D., Founder, Chief Executive Officer and Chair of the Board, will ring the Nasdaq Closing Bell on Tuesday, December 17, 2019, at 4:00 p.m. ET.

The ceremony will take place at the Nasdaq MarketSite, 4 Times Square, in New York. Opening remarks will begin at 3:45 p.m. ET. A live stream of the Nasdaq Closing Bell will be available at:

“We are honored to ring the closing bell in celebration of our recent Nasdaq listing in May. Over the last year, we have made significant progress in the development of our lead programs in Diabetic Cardiomyopathy and Galactosemia,” said Shoshana Shendelman, Ph.D., Founder, CEO and Chair of the Board, Applied Therapeutics. “We thank everyone for their continued support and confidence in Applied, particularly our employees, shareholders, Scientific Advisory Board and Board of Directors. We are excited to be celebrating this special occasion with our dedicated team as we move forward with our mission to create transformative treatments for patients who desperately need them.”

About Applied Therapeutics
Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The company’s lead drug candidate, AT-001, is a novel aldose reductase inhibitor (ARI) that is being developed for the treatment of Diabetic Cardiomyopathy, or DbCM, a fatal fibrosis of the heart. The company initiated a Phase 3 registrational study in DbCM in September 2019. Applied Therapeutics is also developing AT-007, a central nervous system penetrant ARI, for the treatment of Galactosemia, a rare pediatric metabolic disease, and initiated a Phase 1/2 clinical trial in June 2019. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of diabetic retinopathy, expected to advance into a Phase 1 study in 2020.

Forward-looking Statements
This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, included in this press release regarding strategy, future operations, prospects, plans and objectives of management, including words such as "may," "will," "expect," "anticipate," "plan," "intend," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are forward-looking statements. These include, without limitation, statements regarding (i) the design, scope and results of our clinical trials, (ii) the timing of the initiation and completion of our clinical trials, (iii) the likelihood that data from our clinical trials will support future development of our product candidates, (iv) the likelihood of obtaining regulatory approval of our product candidates and qualifying for any special designations, such as orphan drug designation, (v) our cash runway and the timing of our clinical development plan. Forward-looking statements in this release involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and we, therefore cannot assure you that our plans, intentions, expectations or strategies will be attained or achieved. Such risks and uncertainties include, without limitation, the uncertainties inherent in the initiation, execution and completion of clinical trials, in the timing of availability of trial data, in the results of the clinical trials, in the actions of regulatory agencies, in the commercialization and acceptance of new therapies. Factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in our filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” contained therein. Except as otherwise required by law, we disclaim any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.


Maeve Conneighton
(212) 600-1902 or 


Trammy Lai
(917) 297-5956 or

Applied Therapeutics logo.jpg

Source: Applied Therapeutics